BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
KarXT: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Bristol-Myers Squibb. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06585787 A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer Disease | recruiting | 406 |
| 2026-12-09 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT06126224 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Psychosis Associated With Alzheimer's Disease | recruiting | 500 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-02 est. | P3 | Bristol-Myers Squibb BMY | NCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | Bipolar Disorder Type I With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-11-01 est. | P3 | Bristol-Myers Squibb BMY | NCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Bipolar-I Disorder With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-10-05 est. | P3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | NCT05511363 A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Psychosis Associated With Alzheimer's Disease | recruiting | 410 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.